Copy For Citation
EREM C., OZBAS H. M., NUHOĞLU İ., DEGER O., CIVAN N., ERSOZ H. O.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, vol.122, no.5, pp.295-302, 2014 (SCI-Expanded)
-
Publication Type:
Article / Article
-
Volume:
122
Issue:
5
-
Publication Date:
2014
-
Doi Number:
10.1055/s-0034-1370989
-
Journal Name:
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
-
Journal Indexes:
Science Citation Index Expanded (SCI-EXPANDED), Scopus
-
Page Numbers:
pp.295-302
-
Keywords:
gliclazide-MR, metformin, pioglitazone, type 2 diabetes, cardiovascular risk factors, glycemic control, NECROSIS-FACTOR-ALPHA, INSULIN-RESISTANCE, MODIFIED RELEASE, ENDOTHELIAL FUNCTION, DOUBLE-BLIND, ROSIGLITAZONE, MARKERS, PLASMA, HOMOCYSTEINE, INFLAMMATION
-
Karadeniz Technical University Affiliated:
Yes
Abstract
Objective: The objective of this study was to evaluate and compare the effects of gliclazidemodified release (gliclazide-MR), metformine (MET) and pioglitazone (PIO) monotherapies on glycemic control and conventional/non-conventional cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus (T2DM).